January 17, 2020 06:30 AM EST
FDA+

Ger­many’s IQWiG finds first tu­mor-ag­nos­tic drug pro­vides no added ben­e­fit

Zachary Brennan

Senior Editor

Ger­many’s In­sti­tute for Qual­i­ty and Ef­fi­cien­cy in Health Care (IQWiG) this week said that Bay­er’s Vi­t­rakvi (larotrec­tinib), ap­proved in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times